Avatrombopag (Sucoxin) usage and dosage

Avatrombopag is a drug used to treat thrombocytopenia, specifically in patients with chronic liver disease-associated thrombocytopenia and primary immune thrombocytopenia. As the world's first FDA-approved oral thrombopoietin receptor agonist (TPO-RA), avatrombopag has filled the gap in this field in China.

Avatrombopag is produced by Eisai Co., Ltd. in JapanEisai Co., Ltd., and undergoes strict research and development and quality control to ensure its efficacy and safety. This drug helps patients cope with thrombocytopenia by stimulating the proliferation and differentiation of megakaryocytes and increasing platelet production.

The usage and dosage of avatrombopag should be adjusted according to the specific conditions of the patient:

Primary immune thrombocytopenia:

Starting dose:20mg/day, once a day, take with food.

Maximum dose: can be increased to40mg/day, once a day.

Thrombocytopenia associated with chronic liver disease:

Platelet count<40×10^9/L: The recommended dose is 60mg/day, taken orally for 5 days.

The platelet count is between40～<50×10^9/L: the recommended dose is 40mg/day, taken orally for 5 days.

Dosing time: Usually start 10 to 13 days before scheduled surgery or diagnostic procedure

Platelet levels should be monitored regularly during medication and dosage adjustments should be made as necessary. Avatrombopag may interact with other medications, so you should consult your doctor before use. Common side effects of avatrombopag may include fever, abdominal pain, nausea, etc. If you have severe discomfort, you should seek medical attention immediately.

Avatrombopag, as an innovative drug, provides a new treatment option for patients with thrombocytopenia. Its usage and dosage need to be adjusted according to the patient's specific conditions to ensure the effectiveness and safety of the treatment. Before use, be sure to consult a professional doctor and follow medical advice.